Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus METOPROLOL SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus METOPROLOL SUCCINATE.
INDERIDE LA 120/50 vs METOPROLOL SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors. Also suppresses renin release.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
25 to 100 mg orally once daily, titrated at weekly intervals as tolerated; maximum 400 mg/day
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Terminal elimination half-life: 3-7 hours. Twice-daily dosing (metoprolol succinate) provides stable beta-blockade over 24 hours due to extended-release formulation, not due to half-life.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Primarily renal (95% as metabolites, <5% unchanged). Three main metabolites: O-demethylated (active), α-hydroxylated (active), and O-demethylated and α-hydroxylated. Biliary/fecal excretion: <5%.
Category C
Category C
Beta-Blocker/Diuretic Combination
Beta-Blocker